|
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
NOT_RECRUITINGPhase 3Sponsored by Definium Therapeutics US, Inc.
No longer actively recruiting
PhasePhase 3
SponsorDefinium Therapeutics US, Inc.
Started2025-04-14
Est. completion2026-11
Eligibility
Age18 Years – 74 Years
Healthy vol.Accepted
Locations28 sites
View on ClinicalTrials.gov →
NCT06941844
Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Eligibility
Age: 18 Years – 74 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Diagnosis of MDD per DSM-5 2. Male or female aged 18 to 74 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration 4. MADRS Total Score ≥26 5. CGI-S Score ≥4 Exclusion Criteria: 1. Certain psychiatric disorders (other than major depressive disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine 4. Any clinically significant unstable illness
Conditions2
DepressionMajor Depressive Disorder
Locations28 sites
Preferred Research Partner
Fayetteville, Arkansas, 72703
Preferred Research Partners, Inc
Little Rock, Arkansas, 72211
Kadima Neuropsychiatry Institute
Psychedelic Science Institute
Mountain View Clinical Research, Inc
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 3
SponsorDefinium Therapeutics US, Inc.
Started2025-04-14
Est. completion2026-11
Eligibility
Age18 Years – 74 Years
Healthy vol.Accepted
Locations28 sites
View on ClinicalTrials.gov →
NCT06941844